Abstract: Neurodegenerative and dementing illnesses are becoming an increasing social and economical burden as the number of older people continues to grow in industrialized countries. Current knowledge of the processes leading to these diseases is still limited, and very few effective treatments are available. Because neurodegeneration is associated with an activation of injury and innate immune responses in the brain, drugs that could mimic the beneficial aspects of this response are potential therapeutic candidates. The cytokine transforming growth factor (TGF)-β1 is an organizer of the brain's response to injury and is known to be neuroprotective. Previous studies from our lab also showed that TGF-β1 can reduce accumulation of β-amyloid peptide (Aβ), which appears to be central to Alzheimer's disease (AD) pathogenesis, and we therefore initiated a search for small molecule chemical compounds that could mimic this effect. We report here the identification of several such TGF-β mimetics detected in an in vitro screen of a library with 5000 chemically diverse compounds. If active in vivo, these mimetics could be developed into candidates for the treatment of neurodegeneration.
INTRODUCTION
AD is an age-dependent neurodegenerative disorder that causes a progressive cognitive decline. It is characterized by the accumulation of protein deposits in the form of amyloid plaques and cerebrovascular Aβ deposits in the extracellular space. In addition, abnormal phosphorylation of the microtubule associated protein tau results in the formation of tangles inside neurons [1] . These protein deposits are associated with a dramatic loss of neurons in the cortex and hippocampus. Reducing Aβ accumulation is one of the key therapeutic strategies and expected to delay or prevent AD. Aβ may be reduced by decreasing its production or accumulation or by increasing its clearance from the brain. In addition, protecting neurons against Aβ-induced toxicity and cellular stress may also increase their survival and delay disease progression. We have shown that TGF-β1 reduces the number of amyloid plaques in human amyloid precursor protein (hAPP) transgenic mice by up to 75% and reduces overall Aβ accumulation in the brain by 50% [2] . Moreover, mice lacking TGF-β1 show more neurodegeneration, indicating an overall protective effect on neurons [3] .
TGF-β1 is a highly conserved member of the TGF-β superfamily of growth factors. TGF-βs activate the TGF-β signaling pathway through a high-affinity transmembrane receptor complex consisting of the TGF-β type I (ALK5) and type II serine/threonine kinase receptor subunits [4, 5] . TGF-β binding leads to phosphorylation of ALK5 and recruitment and phosphorylation of receptor-regulated Smad2 or Smad3. Once phosphorylated, these Smads associate with Smad4 and translocate into the nucleus where they bind to the Smad-binding element (SBE) present in many different gene promoters to regulate gene transcription [4] . TGF-β1 is *Address correspondence to this author at the Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, and GRECC, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA; Tel: 650-852-3220; E-mail: twc@stanford.edu normally present at low levels in healthy adult brains but is rapidly upregulated after injury and induces expression of many injury response genes [6] . It protects neurons against a diverse number of insults including excitotoxicity, hypoxia, ischemia, deprivation of trophic factors, and exposure to β-amyloid peptide (reviewed in [7, 8] ). TGF-β2 has also been proposed to be neuroprotective in the adult CNS based on its high level neuronal immunoreactivity in human neurodegenerative diseases [7] . In contrast to the trophic and protective effects, in vivo neutralization of TGF-βs during early CNS development prevented ontogenetic neuronal death in the chick embryo ciliary ganglion and retina [9, 10] , indicating that TGF-βs can also trigger neuronal cell death under certain conditions. As mentioned above, TGF-β1 significantly reduces cerebral Aβ accumulation and neuritic dystrophy in a mouse model of AD [2] . TGF-β1's effects are likely mediated by neuronal or glial TGF-β receptors, activation of the TGF-β signaling cascade in neurons and glial cells, and induction of downstream effector genes. TGF-β2 and TGF-β3 bind to the same receptors as TGF-β1 but have different patterns of activation and expression [4, 5] . TGF-β1 can also promote vascular abnormalities and Aβ deposition in cerebral blood vessels, possibly through its effects on TGF-β receptors on endothelial or smooth muscle cells and pericytes [11] . Thus, signals from TGF-β receptors and from other pathways can be integrated differently to result in beneficial or detrimental outcomes [12] [13] [14] . We hypothesize that small-molecule drugs will selectively activate specific elements of the TGF-β signaling pathway, and if administered acutely or over limited periods of time, should allow us to identify compounds with beneficial therapeutic activities.
MATERIALS AND METHODS

Cloning of SBE-SEAP
The SBE promotor, which contains 9 SBE repeats and a herpes simplex virus thymidine kinase minimal promoter (TK) was excised from a SBE 9 -luciferase reporter gene ( [15] , kindly obtained from Dr. D. Vivien, University of Caen, France) using Nhe I and Hind III enzyme restriction sites. The segment was then subcloned into the pSEAP2-Basic plasmid (BD Biosciences, Palo Alto, CA) upstream of the secreted alkaline phospatase (SEAP) coding region.
Reporter Cell Lines
C6 rat astrocytoma cells (CCL-107, ATCC), a spontaneously transformed primary mouse astrocyte cell line (MAB39), and embryonic fibroblasts derived from TGF-β1 knockout mice (MFB; a kind gift from Dr. John Munger, New York University) were stably transfected with the SBE-SEAP reporter plasmid. Cells were transfected in 6-well plates with 1.2 or 6 µg of SBE-SEAP plasmid DNA and 0.12 or 0.6 µg of a hygromycin resistance plasmid using Lipofectin (Invitrogen, Grand Island, New York) following the manufacturer's instructions. Two days later, cells were trypsinized and seeded in 100 mm petri dishes in the presence of 625 or 1250 µg/ml Hygromycin (Invitrogen). Ten days later, isolated colonies were picked using small pieces of filter paper soaked in trysin-EDTA and expanded. Colonies were tested for responsiveness to TGF-β1 using the reporter cell assay described below.
Drug Library
A library with 5000 chemically diverse small molecule compounds (average Mr 500 Da) was obtained from Comgenex LLC (South San Francisco, CA). Compounds were received at a concentration of 20 mM in DMSO and diluted to obtain a working stock of 2 mM in DMSO with an automated pipetting instrument (Precision 2000 from Biotek).
Reporter Cell Assay
To test compounds or to assay individual stably transfected cell lines for responsiveness to TGF-β1, 4 x 10 4 cells were seeded in 10% FBS/DMEM with the Precision 2000 into 96-well plates and incubated overnight. Cells were then washed two times and compounds (20 µM, 4 µM) or recombinant TGF-β1 (0, 30, 100, 300, 1000 pg/ml) were added in serum free medium (DMEM). Medium was taken 24 or 48 h later and assayed for SEAP activity.
SEAP Assay
SEAP activity was measured using the Great EscAPe SEAP Chemiluminescence Detection Kit (BD Biosciences) following the manufacturer's instruction. Briefly, 10 µl of sample medium was mixed with 30 µl of 1 x dilution buffer and incubated at 65 o C for 30 min to eliminate endogenous alkaline phosphatase activity. After the plate was cooled to room temperature, 40 µl of assay buffer was added followed by a 5-min incubation at room temperature and addition of 40 µl of CSPD substrate, which was diluted 1:20 with Chemiluminescent Enhancer. Within 10-60 min after the addition of the substrate, the plates were read on a Lmax Microplate Luminometer (Molecular Devices, Sunnyvale, CA) for chemiluminescence detection.
RESULTS AND DISCUSSION
To identify small molecule chemical compounds with potentially beneficial TGF-β-like bioactivity (TGF-β mimetics) we first developed an in vitro screening method. Several groups have generated heterologous promoters consisting of TGF-β1-inducible DNA binding elements fused to luciferase or other reporter genes. We engineered a fusion gene consisting of the SBE minimal promoter sequences [15] and the secreted alkaline phosphatase (SEAP) reporter gene. This construct is valuable for high-throughput screening because SEAP is a highly sensitive reporter and measurements can conveniently be made from cell culture supernatants at different times. The SBE-SEAP reporter was stably transfected into C6 astrocytoma cells, a spontaneously transformed primary astrocyte line, and into mouse embryonic fibroblasts derived from TGF-β1 knockout mice ( Table 1) . Because virtually every cell synthesizes TGF-βs and can activate their own TGF-β receptors in an autocrine fashion, any compound that is identified in a TGF-β reporter screen may simply synergize with TGF-β1 and not induce the reporter in the complete absence of the cytokine. In contrast, TGF-β1 knockout fibroblasts could identify compounds that truly activate the reporter in the absence of any TGF-β1. Transfected cell lines were screened for specificity and for their ability to respond to recombinant TGF-β1 (Table 1, Fig.  1) . To ensure the cell lines were stable, they were passaged for several weeks and retested at least twice. Several of the C6 lines and MFB-F11 have been passaged more than 20 times without loosing the reporter gene and maintaining roughly the same level of inducibility by TGF-β1.
A drug library with 5000 chemically diverse compounds that have been selected for favorable toxicity and solubility characteristics by the manufacurer was used to carry out a first round of screening. All compounds were tested twice in Fig. (1) . MFB-F11 cells (TGF-β1 knockout fibroblast stably expressing SBE-SEAP) or C6-H4 astrocytoma reporter cells were seeded at 4 x 10 4 cells per well in 96-well plates. Recombinant TGF-β1 was added the next day and SEAP activity was measured 48 h later using a commercial kit. Data points are means from triplicate cultures.
Fig. (2).
Compounds with TGF-β1 activity in the absence of TGF-β1 or with synergistic activity. A) 4 x 10 4 MFB-F11 cells were seeded overnight in 96-well plates before compounds were added (20 µM). Supernatants were harvested 48 h later and SEAP activity was meaured using a commercial kit. OD values were compared to a standard curve generated with cells exposed to different concentrations of recombinant TGF-β1 to calculate drug activity. B) Drugs were added to F11 cells as above at various concentrations in the presence of 100 pg/ml recombinant TGF-β1. Compound 11H (dots) shows mainly synergistic activity, 3A (squares) is agonistic and synergistic.
duplicates using the MFB-F11 cell line and a small robotic pipetting instrument. Based on induction of the reporter in any of the replicates tested, 80 compounds were selected. These compounds were then tested again directly using MFB-F11 or C6-H4 cells alone or they were tested with MFB-F11 cells in the presence of 100 pg/ml of recombinant TGF-β1 to test for synergistic activities. Several compounds showed activities up to an equivalent of 130 pg/ml TGF-β1 at 20 µM in the TGF-β1 deficient MFB-F11 cells (Fig. 2A) . Some compounds acted also synergistically with exogenously added TGF-β1 (Fig. 2B) . Together, we selected 25 lead compounds with agonistic and/or synergistic activity out of the various screens. These compounds belong to different chemical groups and have different physico-chemical properties.
The list of compounds out of this initial screen contains several potentially interesting chemical compounds that are now being tested for specificity as well as for in vivo activity in a reporter mouse for the TGF-β signaling pathway. We expect that at least some of the compounds will retain bioactivity in vivo and can be further developed into TGF-β1 mimetics.
